Phase 2 Alzheimer's Disease Trial, Recruiting NCT07033494 Sponsor: Merck Sharp & Dohme LLC Condition: Alzheimer's Disease
Back to Alzheimers Disease

Phase 2 Alzheimer's Disease Trial, Recruiting

NCT07033494
Recruiting Phase 2 🇦🇺 Australian site

voxsanity.com.au · Eligibility summary from public government registries · 18 August 2026 · not medical advice

Who may and may not be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who may be able to join

  • You have been diagnosed with mild memory or thinking problems (mild cognitive impairment) or mild dementia caused by Alzheimer's disease
  • You have a trusted person (such as a family member or close friend) who is willing and able to support you and take part in the study alongside you
  • If you are already taking an approved Alzheimer's medication, your dose must have stayed the same for at least 3 months before joining

Who may not be able to join

Each point below is a reason the trial team may not be able to accept someone. It is not a list of requirements to meet.

  • You have a known history of stroke or disease affecting the blood vessels in the brain
  • You have been diagnosed with another brain or nervous system condition (other than Alzheimer's) that affects your thinking or memory long-term
  • You have a structural problem with the brain (confirm with trial site)
  • You have had seizures or epilepsy at any point in the last 5 years
  • You have had a significant brain injury, or an infection that has affected how your brain works
  • You have had a serious or unstable medical condition in the 3 months before joining
  • You have a severe ongoing physical or mental health condition, or abnormal results from medical tests (confirm with trial site)
  • You have an immune system condition that is not well controlled, or that requires treatment with certain medications that affect the immune system
  • You have a bleeding disorder that is not well controlled
  • You have been diagnosed with cancer within the last 5 years
  • You have a condition or risk factor that affects the electrical activity of your heart in a specific way (confirm with trial site)
  • You have liver disease
  • You are unwilling or unable to have CT, PET, or MRI scans
  • You currently live in a nursing home or care facility where you need continuous medical or nursing care

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 17 August 2026

Contact this trial

Principal Investigator: Medical Director, Merck Sharp & Dohme LLC

Phone: 1-888-577-8839

Australian sites

Southern Neurology ( Site 0306), Kogarah, New South Wales
+61408455183
KARA Institute for Neurological Diseases ( Site 0302), Macquarie Park, New South Wales
+61289607788
Austin Health ( Site 0300), Ivanhoe, Victoria
61394962181
HammondCare ( Site 0301), Malvern, Victoria
+61395976568

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 2
Registry
ClinicalTrials.gov
Start date
16 July 2025
Est. completion
30 April 2029

Where this trial is recruiting

🇦🇷 Argentina 🇦🇺 Australia 🇧🇪 Belgium 🇨🇦 Canada 🇯🇵 Japan 🇳🇱 Netherlands 🇸🇬 Singapore 🇰🇷 South Korea 🇪🇸 Spain 🇬🇧 United Kingdom 🇺🇸 United States

4 site(s) in Australia. Confirm current status and contact details directly with the trial site.

Primary endpoints

Change from Baseline in Tau PET Standardized Uptake Value Ratio (SUVr); Number of Participants Who Experience One or More Adverse Events (AEs); Number of Participants Who Discontinue Study Intervention Due to an AE

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 17 August 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov